Supernus Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030

Updated on 03/29/2024

Stock Rating
16
Price Target
$40.50
Consensus
Outperform
Upside
24.88%
Analysts
0
Stock Rating
16
Upside
24.88%
Analysts
0
Price Target
$40.50

Supernus Pharmaceuticals Stock Forecast and Price Target

The average target price for Supernus Pharmaceuticals's stock set by renowned analysts in recent months is $40.50, representing a potential upside of approximately 24.88% from its last closing price if met by 2025. This estimation is based on a high estimate of $43.00 and a low estimate of $38.00. If you are interested in SUPN stock, you should also look at its competitors.

$40.50

24.88% Upside

Outperform
Outperform

Supernus Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030

In the last four years, Supernus Pharmaceuticals has seen a decline in its Price, from $39.39 to $0.00 – a 100.00% decrease. In the next year, analysts believe that Fair Value will reach $32.38 – an increase of 100.00%. For the next seven years, the forecast is forFair Value to grow by 100.00%.

2024 Fair Value Forecast
$32.38
2025 Fair Value Forecast
$39.39
2026 Fair Value Forecast
$53.07
2027 Fair Value Forecast
$72.10
2028 Fair Value Forecast
$85.12
2029 Fair Value Forecast
$101.81
2030 Fair Value Forecast
$93.46
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
NOVN Stock Forecast Novartis Outperform 10
CHF88.80 Buy/Sell CHF105.00 23.95%
4502 Stock Forecast Takeda Pharmaceutical Company Outperform 5
¥4.31k Buy/Sell ¥4.74k 6.63%
TEVA Stock Forecast Teva Pharmaceutical Industries Outperform 12
$13.35 Buy/Sell $11.59 19.85%
4151 Stock Forecast Kyowa Kirin Outperform 18
¥2.86k Buy/Sell ¥3.06k 4.82%
JAZZ Stock Forecast Jazz Pharmaceuticals Outperform 14
$116.63 Buy/Sell $188.32 59.52%

Supernus Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030

Supernus Pharmaceuticals's Revenue has seen growth In the last three years, going from $520.40M to $607.52M – a gain of 16.74% In the next year, analysts believe that Revenue will reach $624.59M – an increase of 2.81%. For the next seven years, the forecast is forRevenue to grow by 43.21%.

2024 Rev Forecast
$0.62B
2025 Rev Forecast
$0.65B
2026 Rev Forecast
$0.75B
2027 Rev Forecast
$0.83B
2028 Rev Forecast
$0.90B
2029 Rev Forecast
$0.99B
2030 Rev Forecast
$0.87B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
HIK Stock Forecast Hikma Pharmaceuticals PLC Outperform 18
£19.10 Buy/Sell £28.11 55.34%
ALKS Stock Forecast Alkermes Outperform 10
$28.60 Buy/Sell $33.27 18.88%
PBH Stock Forecast Prestige Consumer Healthcare Outperform 16
$74.58 Buy/Sell $71.50 -0.11%

Supernus Pharmaceuticals Dividend per Share Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BHC Stock Forecast Bausch Health Companies Hold 15
$9.12 Buy/Sell $9.50 -1.32%
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$43.81 Buy/Sell $69.00 41.52%
IRWD Stock Forecast Ironwood Pharmaceuticals Buy 14
$8.95 Buy/Sell $17.83 95.53%

Supernus Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
$0.10B
2025 FCF Forecast
$0.11B
2026 FCF Forecast
$0.17B
2027 FCF Forecast
$0.23B
2028 FCF Forecast
$0.28B
2029 FCF Forecast
$0.34B
2030 FCF Forecast
$0.32B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AMRX Stock Forecast Amneal Pharmaceuticals Outperform 16
$5.38 Buy/Sell $6.13 23.23%
PCRX Stock Forecast Pacira BioSciences Outperform 16
$31.02 Buy/Sell $47.90 45.07%
ANIP Stock Forecast ANI Pharmaceuticals Buy 13
$66.13 Buy/Sell $69.75 20.22%

Supernus Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030

Supernus Pharmaceuticals's EBITDA has decreased In the last three years, from $202.14M to $98.26M – a 51.39% drop. In the following year, 2 experts forecast Supernus Pharmaceuticals's EBITDA will decrease by 2.52%, to $95.78M. The Supernus Pharmaceuticals forecast is for EBITDA to reach $201.26M or grow by 104.82%.

2024 EBITDA Forecast
$0.10B
2025 EBITDA Forecast
$0.14B
2026 EBITDA Forecast
$0.21B
2027 EBITDA Forecast
$0.27B
2028 EBITDA Forecast
$0.21B
2029 EBITDA Forecast
$0.19B
2030 EBITDA Forecast
$0.20B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
COPN Stock Forecast Cosmo Pharmaceuticals N.V. Buy 12
CHF67.50 Buy/Sell CHF76.55 25.82%
COLL Stock Forecast Collegium Pharmaceutical Outperform 11
$37.50 Buy/Sell $37.75 6.67%
BDSI Stock Forecast BioDelivery Sciences Internati... - 11
$5.59 Buy/Sell $10.00 16.46%

Supernus Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030

In the last three years, Supernus Pharmaceuticals's EBIT has seen a drop from $184.00M to $13.40M – a 92.72% decrease. For next year, the 3 analysts predict EBIT of $116.62M, which would mean an increase of 770.30%. Over the next seven years, the pros' prediction is EBITof $406.50M, which would mean a seven-year growth forecast of 2933.58%.

2024 EBIT Forecast
$0.12B
2025 EBIT Forecast
$0.15B
2026 EBIT Forecast
$0.22B
2027 EBIT Forecast
$0.29B
2028 EBIT Forecast
$0.37B
2029 EBIT Forecast
$0.45B
2030 EBIT Forecast
$0.41B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AQST Stock Forecast Aquestive Therapeutics Buy 0
$4.94 Buy/Sell $6.33 61.94%
CHRS Stock Forecast Coherus BioSciences Outperform 6
$2.27 Buy/Sell $10.86 274.45%
ASRT Stock Forecast Assertio Holdings Buy 8
$0.93 Buy/Sell $3.50 276.34%

Supernus Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, Supernus Pharmaceuticals has seen a decline in its EPS, from $2.36 to $0.00 – a 100.00% decrease. In the next year, analysts believe that EPS will reach $1.94 – an increase of 100.00%. For the next seven years, the forecast is forEPS to grow by 100.00%.

2024 EPS Forecast
$1.94
2025 EPS Forecast
$2.36
2026 EPS Forecast
$3.18
2027 EPS Forecast
$4.32
2028 EPS Forecast
$5.10
2029 EPS Forecast
$6.10
2030 EPS Forecast
$5.60
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
EGRX Stock Forecast Eagle Pharmaceuticals - 14
$5.87 Buy/Sell $17.00 -100.00%
DRRX Stock Forecast DURECT Outperform 9
$1.01 Buy/Sell $6.75 568.32%
CPIX Stock Forecast Cumberland Pharmaceuticals - 0
$2.03 Buy/Sell $8.50 -100.00%